Sou Hu Cai Jing·2025-05-08 10:52Core Viewpoint - The company, Zhaoyan New Drug, has experienced a stock price increase of 2.89% to 16.35 yuan, with a rolling PE ratio of 31.63, marking a new low in 16 days, and a total market capitalization of 12.254 billion yuan [1] Company Summary - Zhaoyan New Drug focuses on non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] - The main products include non-clinical research services, clinical services, and experimental model supply [1] - As of the first quarter of 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, and a net profit of 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1] Industry Summary - The average PE ratio for the medical services industry is 38.86, with a median of 38.36, placing Zhaoyan New Drug at the 24th position within the industry [1] - As of the first quarter of 2025, 22 institutions hold shares in Zhaoyan New Drug, including 20 funds, with a total holding of 72.9482 million shares valued at 1.484 billion yuan [1]